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ABSTRACT  
Background: Tremelimumab (CP-675,206) is a fully human monoclonal antibody binding to 
cytotoxic T lymphocyte–associated antigen 4 (CTLA4) on T cells that stimulates the immune 
system by blocking the CTLA4-negative regulatory signal. Combination with standard 
chemotherapy may strengthen antitumor therapy. This is a phase Ib, multi-site, open-label, 
nonrandomized dose escalation trial evaluating the safety, tolerability, and maximum tolerated 
dose (MTD) of tremelimumab combined with gemcitabine in patients with metastatic pancreatic 
cancer.  
Patients and Methods: Gemcitabine (1000 mg/m2 on days 1, 8, and 15 of each 28-day cycles) 
was administrated with escalating doses of intravenous tremelimumab (6, 10, or 15 mg/kg) on day 
1 of each 84-day cycle for a maximum of 4 cycles. The first 18 patients had an initial 4-week 
gemcitabine-only lead-in period. Dose-limiting toxicities (DLTs) related to tremelimumab were 
evaluated during the first 6 weeks after the first dose of tremelimumab.  
Results: From June 2008 to August 2011, 34 patients were enrolled and received at least one 
dose of tremelimumab. No DLTs related to tremelimumab were observed at any dose, even when 
the maximum dose established for tremelimumab (15 mg/kg) was used. Most frequent grade 3/4 
toxicities were asthenia (11.8%) and nausea (8.8%). Only one patient had a serious drug-related 
event (diarrhea with dehydration). The median overall survival was 7.4 months (95% confidence 
interval 5.8–9.4 months). At the end of treatment, two patients achieved partial response, both in 
the tremelimumab 15-mg/kg group (n = 2/19, 10.5%).  
Conclusion: Tremelimumab plus gemcitabine demonstrated a safety and tolerability profile, 
warranting further study in patients with metastatic pancreatic cancer.  
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INTRODUCTION 
Pancreatic cancer is the fourth leading cause of cancer death. Diagnoses are generally made late 
in the disease with a 5-year survival rate <5% [1]. At present, treatment for metastatic disease is 
focused on improving survival and quality of life. 
Since the 1990s, gemcitabine has been the standard treatment for advanced pancreatic cancer [2]. 
Many phase II studies demonstrated the efficacy of gemcitabine combination treatments, but only  
one randomized phase III trial has recently demonstrated improvement in overall survival (OS): 
gemcitabine and nab-Paclitaxel combination compared with gemcitabine alone [3].  A recent phase 
II/III randomized study of combination 5-fluorourcil, leucovorin, irinotecan, and oxaliplatin 
(FOLFIRINOX) versus gemcitabine defined an alternative strategy to gemcitabine monotherapy 
[4]. However, results with current standard therapies clearly underscore the need for new 
treatments. 
Several different immunotherapeutic strategies (vaccination, adoptive cell transfers and targeting 
checkpoints) are being evaluated in pancreatic cancer [5]. In preclinical models, CTLA-4 blockade 
has demonstrated antitumor activity enhancing the endogenous immune response[6,7].  
Tremelimumab (CP-675,206) is a fully humanized monoclonal antibody that binds the cytotoxic T-
lymphocyte–associated antigen 4 molecule (CTLA-4) expressed on the surface of activated T 
lymphocytes and T-regulatory cells. Tremelimumab antagonizes binding of CTLA4 to its target 
ligands (B7-1 and B7-2) by inhibiting its negative regulatory signal to T-cell activation [6]. Blockade 
of inhibitory effects of CTLA4 may allow and potentiate effective immune responses against tumor 
cells . In several clinical studies, anti-CTLA4 agents have been shown to induce durable tumor 
responses through modulation of the immune system in patients with metastatic melanoma [8, 9]. 
Safety of single-agent tremelimumab has been analyzed in several studies in patients with cancer, 
particularly with melanoma. The first-in-human phase I dose-escalation study indicated that 
tremelimumab can safely be administered up to 15 mg/kg, with durable antitumor responses [10]. 
DLTs and autoimmune phenomena included diarrhea, dermatitis, vitiligo, panhypopituitarism, and 
hyperthyroidism. In a subsequent phase I/II study, patients with metastatic melanoma were 
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randomized to receive tremelimumab 10 mg/kg every 28 days or 15 mg/kg every 90 days [11]. The 
15-mg/kg regimen was selected over the 10 mg/kg for further development based on similar 
response rate and OS between the two regimens, but a lower incidence of grade 3/4 adverse 
events (AEs) and serious AEs (SAEs).  
A recent phase II study of single agent ipilimumab reported one delayed response out of 27 
advanced pancreatic cancer. [12]. The present study is the first study of tremelimumab in patients 
with pancreatic cancer. The choice of gemcitabine as combination therapy has been sustained by 
the evidence of its role in increasing immune response  [13, 14]. To provide synergistic antitumor 
activity without increasing toxicity was the rationale for exploring combination tremelimumab plus 
gemcitabine regimen. 
 
PATIENTS AND METHODS 
Patients 
Eligible patients had histologically/cytologically confirmed metastatic pancreatic cancer and had 
not received prior systemic treatment with chemotherapy. Patients were aged 18 years or older 
with an ECOG PS 0 or 1 and adequate hematology, blood chemistry, and renal and liver function. 
Patients were excluded if they had received previous treatment with an anti-CTLA4 agent or 
radiotherapy for locally advanced disease within 4 weeks prior to randomization. Patients with 
inflammatory bowel disease or diarrhea at baseline; history of diverticulitis; or current (or active in 
the last 3 years) chronic inflammatory or autoimmune (except vitiligo) were excluded. All patients 
signed informed consent and the protocol was approved by local ethics committees. The study 
was conducted in accordance with Good Clinical Practice guidelines and the Declaration of 
Helsinki. 
 
Study Design and Treatment 
Study A3671016 (ClinicalTrials.gov: NCT00556023) was a phase Ib, multi-site, open-label, 
nonrandomized dose escalation clinical trial evaluating the safety and tolerability of tremelimumab 
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plus gemcitabine in patients with metastatic pancreatic cancer. Secondary objectives included 
monitoring for preliminary evidence of efficacy for the combination and evaluation of drug 
pharmacokinetics.  
There were four scheduled cycles. The study protocol was amended to allow a patient to receive 
up to 7 cycles. A cycle consisted of one dose of tremelimumab and up to 12 doses of gemcitabine. 
Gemcitabine 1000 mg/m2 was administered for 3 weeks followed by 1 week of rest. Tremelimumab 
was administered by intravenous infusion on day 1 of each 84-day cycle.  
The trial consisted of two treatment portions (Supplementary 1S). Portion A was a 1-month 
gemcitabine-only lead-in period (cycle 0) followed by combination tremelimumab/gemcitabine 
therapy. This lead-in period permitted exclusion of patients with early progression of disease as 
well as patients with gemcitabine-related diarrhea. Patients successfully completing the lead-in 
period were assigned to escalating doses of tremelimumab (6, 10, or 15 mg/kg) in addition to 
gemcitabine, using the standard 3+3 method. Dose escalation proceeded until the maximum 
tolerated dose (MTD) was identified (up to 15 mg/kg). The MTD was defined as the maximum dose 
level of tremelimumab in combination with gemcitabine at which ≤1 of 6 evaluable patients 
experienced  dose-limiting toxicities (DLT) during the first 6 weeks following the first administration 
of tremelimumab (DLT observation window). Portion B commenced once the MTD expansion 
group had completed Portion A.  
Patients enrolled in Portion B initiated therapy with combination tremelimumab/gemcitabine, i.e. 
without a lead-in period. The starting dose of tremelimumab was one dose-level lower than the 
MTD defined in Portion A. Dose escalation proceeded until the MTD was identified (up to 15 
mg/kg). Once the MTD has been identified, a minimum of 12 patients had to be studied at the MTD 
to determine its suitability as recommended dose for further studies. 
DLTs were graded according to the National Cancer Institute  Common Terminology Criteria for 
Common Toxicity 3.0 [15]. A DLT was defined as any grade 4 treatment-related toxicity (except for 
lymphopenia without clinical consequences), or grade 3/4 toxicities not recovering to grade 1 or 
baseline within 7 days of maximal management and/or after delaying the gemcitabine infusion by a 
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maximum of 2 weeks (except lymphopenia, alopecia, and skin rash not requiring systemic steroid 
therapy or other immunosuppressive therapy), or grade 2–4 autoimmune toxicity of critical organs 
(except anterior uveitis), or failure to recover to grade 1 or baseline severity for drug-related toxicity 
after delaying the initiation of gemcitabine infusion by a maximum of 2 weeks. 
Three or six patients were enrolled per dose level, based on the number of DLTs observed at that 
dose level. Treatment continued until disease progression, as defined by the 1st radiologic 
assessment without further confirmation, unacceptable toxicity, or consent withdrawal. 
 
Assessments 
Patients were assessed at baseline and throughout the trial with a complete physical examination, 
collection of signs and symptoms, and hematology/biochemistry. Tumors were assessed by 
computed tomography at baseline and every 8+2 weeks. Best overall response was determined 
according to the Response Evaluation Criteria in Solid Tumors 1.0 guidelines [16]. 
 
Pharmacokinetic (PK) Evaluations. 
Blood samples for gemcitabine PK analyses were obtained prior to administration, at the end of the 
infusion, and 0.5, 1, 2, 3, 4, and 6 hours post-infusion in Cycle 0 on Day 1 and in Cycle 1 on Day 1. 
Blood specimens for assay of tremelimumab PK were obtained just prior to administration and 1 
hour after the end of the infusion in Cycle 1 on Day 1. Blood specimens of tremelimumab were 
also obtained in Cycle 1 on Days 8, 29, and 57. 
Tremelimumab PK data following tremelimumab given alone in the A3671008 study [9], ere 
compared with these following tremelimumab given with gemcitabine in this study.   
The concentration-time data were analyzed by non-compartmental analysis. Parameters of drug 
exposure included area under the concentration curve from time zero to the last quantifiable 
concentration (AUClast) and to infinity (AUCinf).  
AUCinf was calcuated as: 
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(AUCinf) = AUC0–last + The last concentration/Ke,   
Where Ke was the elimination rate constant calculated from the slope of the line plotted as at least 
3 points of concentration versus time and having a regression coefficient (R2) of at least 0.90. 
These criteria were used for the calculation of AUCinf 
 
Statistical Analysis 
Summary statistics with 95% confidence intervals (CIs) were calculated for continuous variables 
and discreet variables. Kaplan-Meier estimators and curves were created to estimate time-to-event 
end points, OS, and progression-free survival. Pearson chi-square test or Fisher’s exact test was 
used to compare proportions as appropriate. 
 
RESULTS 
Patient Characteristics  
Thirty-eight patients were enrolled in five centers from June 2008 to August 2011. Two patients 
withdrew consent after 3 weeks of the gemcitabine lead-in period and two patients were excluded 
from analysis because they did not meet inclusion/exclusion criteria. Baseline demographic 
characteristics are summarized in Table 1.  
 
Study Treatment 
Thirty-four patients received at least one dose of tremelimumab in combination with gemcitabine. 
Eighteen patients were enrolled into portion A and 16 patients into Portion B. Four patients 
received tremelimumab 6 mg/kg (cohort-6), 8 received tremelimumab 10 mg/kg (cohort-10), and 
22 received tremelimumab 15 mg/kg (cohort-15).  
Patients received a median of two tremelimumab infusions (range 1–7). Median number of cycles 
was 1.5 (range 1–2), 1.5 (range 1–7), and 2.0 (range 1–4) in cohorts-6, 10, and 15, respectively. 
During the lead-in period, four patients had one dose of gemcitabine withheld due to hematologic 
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toxicities (neutropenia or thrombocytopenia). Gemcitabine dose was reduced in four patients due 
to hematologic toxicities (neutropenia or thrombocytopenia). Tremelimumab dose was never 
delayed. The main reasons for withdrawal were disease progression and non–treatment-related 
SAEs. 
 
Toxicity 
Treatment-related toxicities are summarized in Table 2. No DLTs occurred during the study. There 
was no clear trend in AEs across the different dose cohorts. Also, there was no significant 
difference in the event rate for diarrhea between patients in Portions A (33.3% - 6/18 patients) and 
B (31.2% - 5/16 patients); however, grade 3/4 diarrhea were reported in two patients in Portion B 
and none in Portion A.  
Only two patients experienced autoimmune toxicities (hyperthyroidism and vitiligo).  
Eleven patients experienced at least one SAE; one patient (cohort-10/Portion B) had an SAE 
(diarrhea and dehydration) related to tremelimumab/gemcitabine treatment and died 2 weeks after 
the onset despite hospitalization and maximal supportive care. Other non–treatment-related SAEs 
included one of each of the following: acute coronary ischemic event, pulmonary embolism, 
hyperbilirubinemia, and hematemesis in cohort-10 and acute renal failure, and gastrointestinal 
hemorrhage, and two hyperbilirubinemia in cohort-15. Treatment was withdrawn in these patients.  
Treatment was temporarily discontinued in four patients who experienced hyperbilirubinemia for 
biliary stent occlusion (cohort-6/Portion A), vertigo for labyrinthitis (cohort-6/Portion A), and acute 
coronary ischemic event (cohort-10/Portion B).  
 
Clinical Outcome 
Tumor response was evaluable in 28 patients. Six patients were not evaluated because of 
premature withdrawal without disease re-evaluation. In the response-evaluable group, two patients 
(cohort-15/Portion A) who received two and four cycles of treatment, respectively, achieved a best 
overall response of partial response at 8 weeks. Duration of objective response for these two 
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responders was not calculated because no progression date was recorded for either patient; 
consequently, both were censored dead with no progression documented.  
Seven patients had stable disease for >10 weeks. Two patients with stable disease completed the 
study (≥4 cycles of tremelimumab) and one continued treatment with stable disease for seven 
cycles. However, this patient later died for reasons not related to ongoing treatment.  
Most patients in each cohort died due to progressive disease. However, six (17.6%) patients in 
cohort-15 were alive at the time of analysis. With a median follow-up time of 7.1 (95% CI 5.4-8.7) 
months, median OS (95% CI) was 5.3 (1.2–14.6), 8.0 (2.3–16.9), and 7.5 (6.0–9.5) months in 
cohort-6, cohort-10, and cohort-15, respectively. For all patients, median survival was 7.4 (95% CI 
5.8–9.4) months (Supplementary 2S). Due to the limited number of patients in each cohort, all CIs 
were wide and overlapped with each other. 
 
Pharmacokinetics 
Pharmacokinetic data are reported only for patients in cohort-15 because the sample size was too 
small in cohort-6 and cohort-10. Plasma profiles and pharmacokinetic parameters of gemcitabine 
were similar in the presence and absence of tremelimumab (Supplementary 3S). The mean area 
under the curve (AUClast) was 6114 ± 4104 hr*ng/mL (n = 10) and 7441 ± 5479 hr*ng/mL (n = 7) in 
the presence and absence of tremelimumab, respectively, with ratio of 0.82 in the two groups. Two 
plasma curves of tremelimumab in the presence and absence of gemcitabine overlapped. Mean 
AUC of tremelimumab/gemcitabine in this study were compared with results for tremelimumab 
given alone in the A3671008 study in patients with advanced refractory or relapsed melanoma 
(Supplementary 4S) [9].Since there were differences in PK sampling  times between the 2 studies, 
the PK parameter of the AUCinf in 5 patients (the concentration-time data from other 5 patients did 
not meet the criteria for the calculation of AUCinf) instead of using  AUClast in 10 patients in this 
study was chosen to compare with that from A3671008 study. Mean AUCinf was 112,900 ± 39,275 
hr·µg/mL (n = 5) and 112,719 ± 40,933 hr·µg/mL (n = 150) in the presence and absence of 
gemcitabine, respectively, with a ratio of 1.0 in the two groups.  
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Overall, our analysis indicates that the combination regimen can be administered without 
PKinteractions. 
 
DISCUSSION 
This study demonstrated that tremelimumab can be safely administered at the dose of 15 mg/kg in 
a 84-day cycle in combination with gemcitabine. The tremelimumab regimen used is similar to that 
of other phase I-II studies of tremelimumab monotherapy [17, 18]. It can be inferred from these 
results that addition of gemcitabine did not appear to increase toxicity relative to administration of 
tremelimumab alone and there was no apparent modification in gemcitabine PK.  
The majority (94.1%) of patients experienced at least one treatment-related AE; most frequently 
thrombocytopenia, diarrhea, nausea, hypertransaminasemia, asthenia, anemia, neutropenia, and 
fever. However, grade 3 toxicities occurred much less frequently, and included neutropenia, 
asthenia, and nausea. One patient had grade 5 nonhematologic treatment-related toxicity 
(diarrhea/dehydration). Two additional grade 4 nonhematologic toxicities (pulmonary embolism and 
gastrointestinal bleeding) were not attributed to treatment. 
Previous studies with tremelimumab [10, 11, 17, 18] reported autoimmune or autoinflammatory 
side effects thought to be caused by activated T cells. The most frequently observed (>20%–30%) 
treatment-emergent AEs among these trials were rash, nausea, diarrhea, fatigue, and pruritus. 
Further, AEs appeared to increase with dose. Immune-mediated AEs in previous studies were, in 
general, hyperthyroidism, vitiligo, psoriasis, and hypophysitis and grade 3/4 diarrhea reported in 
<10% of cases [10, 11, 17, 18]. In the present study, toxicity associated with 
tremelimumab/gemcitabine did not appear to be greater than that of tremelimumab monotherapy. 
In addition, in this study, there was a lower incidence of grade 3/4 diarrhea compared with previous 
studies [10, 11, 17, 18]. In this regard, patients in the current study were divided into two groups 
(Portions A and B) to determine whether the timing of adding tremelimumab to gemcitabine 
treatment would significantly affect the frequency of treatment-emergent diarrhea. Grade 3/4 
diarrhea occurred only in two Portion B patients (one each in cohorts-10 and 15). There was no 
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statistically significant difference in the proportion of patients with ≥1 treatment-emergent cases of 
diarrhea over all cycles between Portions A and B (33% versus 40%, respectively, P = 0.714) with 
tremelimumab 10-mg/kg or between Portions A and B (45% versus 27%, respectively, P = 0.505) 
in the 15-mg/kg group. Therefore, addition of tremelimumab did not appear to affect the frequency 
of treatment-emergent diarrhea. However, patients receiving tremelimumab 15 mg/kg in both 
Portions A and B experienced significantly earlier onset of diarrhea and shorter median duration of 
cumulative diarrhea-event days versus tremelimumab 10-mg/kg–treated patients (data not shown). 
Although these cohorts may not be large enough to give statistically meaningful conclusion, across 
the 10-mg/kg and 15-mg/kg tremelimumab dose groups, patients in Portion B tended to experience 
earlier onset of diarrhea compared with Portion A.  
Grade 3 toxicities increased with increasing dose level, in particular, for thrombocytopenia, 
nausea, diarrhea, anemia, neutropenia, and asthenia. In the response-evaluable group, two 
patients achieved a best overall response of partial response and seven patients achieved stable 
disease for >10 weeks. Duration of objective responses was not calculated because no 
progression date was recorded for either patient.  
Experience with other anti-CTLA4 agents, suggested a different pattern of response following 
immunotherapy [11, 18]. Initial increase in tumor burden during immunotherapy can be the effect of 
a heavy infiltrate of tumor site by immune and inflammatory cells. Evaluation for new response 
criteria are ongoing [19]. It is possible that, in patients without tumor response, continuation of 
treatment and observation would later provide benefits. The recent phase II study of ipilimumab in 
pancreatic cancer seems to confirm this hypothesis.[12].  
The present study showed that tremelimumab in combination with gemcitabine demonstrated a 
safety and tolerability profile warranting further study and, in those patients who received 10 or 15 
mg/kg tremelimumab, OS was longer than expected, based on historical data [3, 4], versus 
gemcitabine monotherapy. Phase II studies of tremelimumab in metastatic pancreatic cancer could 
address this point. 
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LEGEND TO FIGURES  
 
Supplementary 1S. Study schema. 
Supplementary 2S. Kaplan-Meier plot of overall survival. GEM, gemcitabine. 
Supplementary 3S. Median AUC for gemcitabine in cohort-15 during the lead-in period (cycle 0 
week 1) and in association with tremelimumab 15 mg/kg (cycle 1 week 1). AUC, area under the 
plasma concentration–time curve. 
Supplementary 4S. Median AUC for tremelimumab in combination with gemcitabine versus 
gemcitabine alone in the A3671008 study in melanoma [12]. AUC, area under the plasma 
concentration–time curve; GEM, gemcitabine. 
